Trial · NCT02290106

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

NCT02290106, Not applicable, Completed, Massachusetts General Hospital; results first posted 2019-07-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effects of Pitavastatin on Insulin Sensitivity and Liver Fat. Trials, record NCT02290106. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02290106

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effects of Pitavastatin on Insulin Sensitivity and Liver Fat
NCT number: NCT02290106
Status: Completed
Phases: Not applicable
Enrollment: 50 participants, actual
Lead sponsor: Massachusetts General Hospital
Conditions: Obesity, Fatty Liver, Nonalcoholic
Interventions: pitavastatin, PLACEBO
First posted: 2014-11-13
Last updated: 2019-07-02
Results first posted: 2019-07-02

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Insulin-stimulated Glucose Uptake	6 months	insulin-stimulated glucose uptake measured by euglycemic hyperinsulinemic clamp
Primary	Liver Fat	6 months	liver fat content as measured by 1H-magnetic resonance spectroscopy
Secondary	Alanine Aminotransferase (ALT)	6 months	alanine aminotransferase at the 6 month timepoint
Secondary	Aspartate Aminotransferase (AST)	6 months	aspartate aminotransferase at 6 month timepoint
Secondary	Hepatic Insulin Sensitivity	6 months	hepatic insulin sensitivity assessed by glucose infusion rate corrected for fluctuations in serum glucose ("M") during low-dose insulin clamp
Secondary	Hemoglobin A1c (HbA1c)	6 months
Secondary	Quantitative Insulin Sensitivity Check Index (QUICKI)	6 months	quantitative insulin sensitivity check index (QUICKI) at 6 months. Measure = 1/((log(glucose in mg/dL) + log(insulin in uU/mL))

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Insulin-stimulated Glucose Uptake	6 months	All patients with results for baseline and final. In addition to 3 participants who did not finish the study, 2 participants were unable to undergo clamp.	mg/kg/minute	MEAN
PRIMARY	Liver Fat	6 months	All participants with baseline and final data were analyzed. In addition to patients who discontinued from the study, some patients were unable to have MRI scan due to inability to fit in the scanner or unanticipated claustrophobia.	% liver fat (hepatic fat fraction)	MEAN
SECONDARY	Alanine Aminotransferase (ALT)	6 months	all patients with available data at baseline and final	U/L	MEAN
SECONDARY	Aspartate Aminotransferase (AST)	6 months	all patients with available data at baseline and final	U/L	MEAN
SECONDARY	Hepatic Insulin Sensitivity	6 months	all patients with available data at baseline and final (note, in addition to 3 patients who discontinued, some patients were unable to undergo clamp procedure)	mg/kg/minute	MEAN
SECONDARY	Hemoglobin A1c (HbA1c)	6 months		% (hemoglobin A1c)	MEAN
SECONDARY	Quantitative Insulin Sensitivity Check Index (QUICKI)	6 months		QUICKI index	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Insulin-stimulated Glucose Uptake	Pitavastatin	5.9	Standard Deviation 2.1	mg/kg/minute
Insulin-stimulated Glucose Uptake	Placebo	5.9	Standard Deviation 1.6	mg/kg/minute
Liver Fat	Pitavastatin	17	Standard Deviation 11	% liver fat (hepatic fat fraction)
Liver Fat	Placebo	14	Standard Deviation 10	% liver fat (hepatic fat fraction)
Alanine Aminotransferase (ALT)	Pitavastatin	37	Standard Deviation 38	U/L
Alanine Aminotransferase (ALT)	Placebo	27	Standard Deviation 17	U/L
Aspartate Aminotransferase (AST)	Pitavastatin	31	Standard Deviation 23	U/L
Aspartate Aminotransferase (AST)	Placebo	26	Standard Deviation 12	U/L
Hepatic Insulin Sensitivity	Pitavastatin	1.5	Standard Deviation 1.0	mg/kg/minute
Hepatic Insulin Sensitivity	Placebo	1.6	Standard Deviation 0.7	mg/kg/minute

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pitavastatin	25
Overall Study	STARTED	Placebo	25
Overall Study	COMPLETED	Pitavastatin	24
Overall Study	COMPLETED	Placebo	23
Overall Study	NOT COMPLETED	Pitavastatin	1
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events18

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhea or Loose Stools	Gastrointestinal disorders	Pitavastatin	3	25
other	Diarrhea or Loose Stools	Gastrointestinal disorders	Placebo	7	25
other	Any Gastrointestinal Symptoms	Gastrointestinal disorders	Pitavastatin	5	25
other	Any Gastrointestinal Symptoms	Gastrointestinal disorders	Placebo	8	25
other	Any Musculoskeletal Symptoms	Musculoskeletal and connective tissue disorders	Pitavastatin	4	25
other	Any Musculoskeletal Symptoms	Musculoskeletal and connective tissue disorders	Placebo	6	25
other	Muscle Cramps	Musculoskeletal and connective tissue disorders	Pitavastatin	4	25
other	Muscle Cramps	Musculoskeletal and connective tissue disorders	Placebo	4	25
other	Fatigue	General disorders	Pitavastatin	2	25
other	Fatigue	General disorders	Placebo	5	25

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pitavastatin	0	25
Total, all-cause mortality	Placebo	0	25
Total, other adverse events	Pitavastatin	16	25
Total, other adverse events	Placebo	25	25
Total, serious adverse events	Pitavastatin	2	25
Total, serious adverse events	Placebo	1	25

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30239757	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Pitavastatin vs Placebo: deaths from any cause	Trial comparisons
Pitavastatin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02290106

GET https://conductscience.org/api/trials/v1/NCT02290106/registered

API reference For AI assistants